Today's Analyst Stock Ratings | Upgrades, Downgrades

SPY752.16−0.29%QQQ681.66−0.53%BTC/USD76,668.29−0.87%DIA515.40−0.32%GLD360.39+0.32%TLT81.29+0.22%

							Get Alert
Nov 2, 2026	DRUGBright Minds Biosciences	$21.00	76.19%	Thomas ShraderBTIG 50%	37 147	Previous Buy Current Buy	Get Alert
Nov 2, 2026	NSSCNAPCO Security Techs	$31.77	35.35%	James RicchiutiNeedham 81%	43 49	Previous Buy Current Buy	Get Alert
Nov 2, 2026	FMCFMC	$6.12	14.38%	Frank MitschFermium Research 53%	6 7	Previous Hold Current Hold	Get Alert
Nov 2, 2026	MRKMerck & Co	$143.85	-2.68%	Ilya ZubkovFreedom Broker 48%	125 140	Previous Hold Current Hold	Get Alert
Nov 2, 2026	HHyatt Hotels	$185.44	11.09%	Manuchekhr NarzulloevFreedom Broker 61%	192 206	Previous Buy Current Buy	Get Alert
Nov 2, 2026	PBFPBF Energy	$77.73	-18.95%	Sergey PigarevFreedom Broker 77%	55 63	Previous Sell Current Hold	Get Alert
Nov 2, 2026	USLMUnited States Lime	$121.04	8.23%	Vitaly KononovFreedom Broker 69%	131 132	Previous Buy Current Buy	Get Alert
Nov 2, 2026	IPIIntrepid Potash	$29.50	38.98%	Vitaly KononovFreedom Broker 69%	41 44	Previous Buy Current Buy	Get Alert
Nov 2, 2026	CFCF Industries Holdings	$116.90	10.35%	Vitaly KononovFreedom Broker 69%	129 133	Previous Hold Current Hold	Get Alert
Nov 2, 2026	MOSMosaic	$17.81	-4.55%	Vitaly KononovFreedom Broker 69%	17 17	Previous Sell Current Hold	Get Alert
Nov 2, 2026	VALEVale	$11.05	-14.02%	Vitaly KononovFreedom Broker 69%	9.5 12	Previous Buy Current Buy	Get Alert
Nov 2, 2026	AEMAgnico Eagle Mines	$167.24	26.76%	Vitaly KononovFreedom Broker 69%	212 212	Previous Hold Current Buy	Get Alert
Nov 2, 2026	OKEONEOK	$91.94	19.64%	Sergey PigarevFreedom Broker 77%	105 110	Previous Buy Current Buy	Get Alert
Nov 2, 2026	MSEXMiddlesex Water	$57.64	0.62%	Matvey TaytsFreedom Broker 49%	56 58	Previous Hold Current Hold	Get Alert
Nov 2, 2026	TXTTextron	$87.77	15.07%	Sergey GlinyanovFreedom Broker 76%	101 108	Previous Buy Current Buy	Get Alert
Nov 2, 2026	MARMarriott International	$412.98	-2.9%	Chad BeynonMacquarie 53%	372 401	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	ALKAlaska Air Group	$36.82	30.36%	Atul MaheswariUBS 53%	48 51	Previous Buy Current Buy	Get Alert
Nov 2, 2026	PZZAPapa John's International	$18.56	13.15%	Dennis GeigerUBS 55%	21 28	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	CRICarter's	$31.31	5.4%	Jay SoleUBS 66%	33 38	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	WTWWillis Towers Watson	$327.66	20.55%	Brian MeredithUBS 73%	395 398	Previous Buy Current Buy	Get Alert
Nov 2, 2026	VALEVale	$11.05	22.19%	Caio GreinerUBS 75%	13.5 14.5	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	SYFSynchrony Financial	$75.20	6.38%	Erika NajarianUBS 64%	80 81	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	RYANRyan Specialty Holdings	$45.73	13.71%	Brian MeredithUBS 73%	52 55	Previous Buy Current Buy	Get Alert
Nov 2, 2026	PNCPNC Financial Services Gr	$229.41	21.18%	Erika NajarianUBS 64%	278 286	Previous Buy Current Buy	Get Alert
Nov 2, 2026	GSGoldman Sachs Group	$893.99	11.86%	Erika NajarianUBS 64%	1K 1.01K	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	COFCapital One Financial	$207.99	31.74%	Erika NajarianUBS 64%	274 280	Previous Buy Current Buy	Get Alert
Nov 2, 2026	BROBrown & Brown	$70.92	1.52%	Brian MeredithUBS 73%	72 73	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	BFHBread Financial Holdings	$106.26	12.93%	Nicholas HolowkoUBS 56%	120 127	Previous Buy Current Buy	Get Alert
Nov 2, 2026	AONAon	$330.16	7.83%	Brian MeredithUBS 73%	356 387	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	BACBank of America	$49.59	25.04%	Erika NajarianUBS 64%	62 67	Previous Buy Current Buy	Get Alert
Nov 2, 2026	ALLYAlly Financial	$38.47	24.78%	Erika NajarianUBS 64%	48 50	Previous Buy Current Buy	Get Alert
Nov 2, 2026	KVUEKenvue	$19.60	2.04%	Peter GromUBS 62%	19 20	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	MSMorgan Stanley	$185.60	29.31%	Erika NajarianUBS 64%	236 240	Previous Buy Current Buy	Get Alert
Nov 2, 2026	JPMJPMorgan Chase	$337.56	18.5%	Erika NajarianUBS 64%	395 400	Previous Buy Current Buy	Get Alert
Nov 2, 2026	USBU.S. Bancorp	$59.49	10.94%	Erika NajarianUBS 64%	64 66	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	AXPAmerican Express	$325.10	6.43%	Erika NajarianUBS 64%	345 346	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	XOMExxonMobil Holdings	$177.88	19.74%	Manav GuptaUBS 74%	199 213	Previous Buy Current Buy	Get Alert
Nov 2, 2026	RNRRenaissanceRe Holdings	$346.84	5.52%	Brian MeredithUBS 73%	349 366	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	NWLNewell Brands	$5.63	2.15%	Peter GromUBS 62%	5.5 5.75	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	EGEverest Group	$410.57	3.03%	Brian MeredithUBS 73%	395 423	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	CPRICapri Holdings	$20.00	-5%	Jay SoleUBS 66%	17 19	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	CHDChurch & Dwight Co	$109.16	2.6%	Peter GromUBS 62%	106 112	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	BLMNBloomin Brands	$10.23	12.41%	Dennis GeigerUBS 55%	9 11.5	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	AJGArthur J. Gallagher	$273.45	17.02%	Brian MeredithUBS 73%	299 320	Previous Buy Current Buy	Get Alert
Nov 2, 2026	ACGLArch Capital Group	$107.79	15.97%	Brian MeredithUBS 73%	120 125	Previous Buy Current Buy	Get Alert
Nov 2, 2026	CVXChevron	$225.80	17.36%	Josh SilversteinUBS 69%	235 265	Previous Buy Current Buy	Get Alert
Nov 2, 2026	AMBQAmbiq Micro	$45.30	10.38%	Timothy ArcuriUBS 86%	50 73	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	CEVACEVA	$29.50	35.59%	Natalia WinklerUBS 48%	40 48	Previous Buy Current Buy	Get Alert
Nov 2, 2026	CBRSCerebras Systems	$97.23	157.11%	Timothy ArcuriUBS 86%	250 330	Previous Buy Current Buy	Get Alert
Nov 2, 2026	UBERUber Technologies	$66.45	59.52%	Stephen JuUBS 73%	106 110	Previous Buy Current Buy	Get Alert
Nov 2, 2026	LYFTLyft	$16.67	7.98%	Stephen JuUBS 73%	17 18	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	BTSGBrightSpring Health	$69.74	31.92%	A.J. RiceUBS 73%	85 92	Previous Buy Current Buy	Get Alert
Nov 2, 2026	DVADaVita	$182.17	57.55%	A.J. RiceUBS 73%	270 287	Previous Buy Current Buy	Get Alert
Nov 2, 2026	CLColgate-Palmolive	$95.62	17.13%	Peter GromUBS 62%	106 112	Previous Buy Current Buy	Get Alert
Nov 2, 2026	SXTSensient Technologies	$116.87	31.77%	Joshua SpectorUBS 61%	154 157	Previous Buy Current Buy	Get Alert
Nov 2, 2026	TDOCTeladoc Health	$8.75	2.83%	Kevin CaliendoUBS 72%	6.5 9	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	ABBVAbbVie	$285.06	3.49%	Michael YeeUBS 72%	275 295	Previous Neutral Current Neutral	Get Alert
Nov 2, 2026	XELXcel Energy	$78.76	19.35%	Nicholas CampanellaBarclays 64%	85 94	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	VLTOVeralto	$116.47	10.76%	William GrippinBarclays 38%	117 129	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	VALEVale	$11.05	31.24%	Amos FletcherBarclays 65%	14.5 15	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	TPGTPG	$48.39	28.13%	Benjamin BudishBarclays 70%	61 62	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	TIMBTIM	$17.97	22.43%	Mathieu RobilliardBarclays 64%	22 24	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	HSYHershey	$167.54	2.07%	Andrew LazarBarclays 50%	171 178	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	FTITechnipFMC	$66.74	34.85%	David AndersonBarclays 70%	86 90	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	RSGRepublic Services	$242.87	4.58%	William GrippinBarclays 38%	240 254	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	PFSIPennyMac Financial Servs	$63.90	4.85%	Terry MaBarclays 46%	67 71	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	OMFOneMain Holdings	$56.02	5.32%	Terry MaBarclays 46%	59 60	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	SPGIS&P Global	$460.00	24.35%	Manav PatnaikBarclays 70%	553 572	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	MSCIMSCI	$639.78	18.79%	Manav PatnaikBarclays 70%	735 760	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	MHKMohawk Industries	$145.36	-14.01%	Matthew BouleyBarclays 64%	115 125	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	MBLYMobileye Global	$5.59	25.23%	Dan LevyBarclays 50%	7 9	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	LYBLyondellBasell Industries	$66.09	4.4%	Aleksey YefremovBarclays 62%	66 69	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	KYMRKymera Therapeutics	$128.17	32.64%	Eliana MerleBarclays 62%	139 170	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	FSLRFirst Solar	$191.00	20.42%	Christine ChoBarclays 58%	230 259	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	HGVHilton Grand Vacations	$41.76	-6.61%	Brandt MontourBarclays 60%	39 46	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	EMNEastman Chemical	$65.34	13.25%	Aleksey YefremovBarclays 62%	72 74	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	DVADaVita	$182.17	18.57%	Andrew MokBarclays 62%	216 224	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	DANDana	$23.57	40.01%	Dan LevyBarclays 50%	33 35	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	CVXChevron	$225.80	8.06%	Betty JiangBarclays 60%	208 244	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	CBOECboe Global Markets	$345.00	13.62%	Benjamin BudishBarclays 70%	343 392	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	CPRICapri Holdings	$20.00	20%	Adrienne YihBarclays 67%	19 24	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	CNICanadian National Railway	$126.30	4.51%	Brandon OglenskiBarclays 64%	130 132	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	CCJCameco	$72.56	22.66%	Richard GarchitorenaBarclays 59%	89 95	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	BFAMBright Horizons Family	$53.24	50.26%	Manav PatnaikBarclays 70%	80 95	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	BWABorgWarner	$52.00	53.85%	Dan LevyBarclays 50%	80 85	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	CARAvis Budget Gr	$101.14	13.7%	Dan LevyBarclays 50%	115 160	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	PIImpinj	$185.15	17.2%	Guy HardwickBarclays 72%	200 217	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	TELTE Connectivity	$220.00	38.18%	Guy HardwickBarclays 72%	300 304	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	MANHManhattan Associates	$255.14	7.78%	Guy HardwickBarclays 72%	239 275	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	APHAmphenol	$84.10	31.99%	Guy HardwickBarclays 72%	100 111	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	AEPAmerican Electric Power	$129.39	2.02%	Nicholas CampanellaBarclays 64%	120 132	Previous Equal-Weight Current Equal-Weight	Get Alert
Nov 2, 2026	MOAltria Group	$76.86	-21.94%	Pallav MittalBarclays 42%	58 60	Previous Underweight Current Underweight	Get Alert
Nov 2, 2026	ALNYAlnylam Pharmaceuticals	$159.09	138.86%	Eliana MerleBarclays 62%	380 450	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	AEMAgnico Eagle Mines	$167.24	28.56%	Richard GarchitorenaBarclays 59%	215 218	Previous Overweight Current Overweight	Get Alert
Nov 2, 2026	ABBVAbbVie	$285.06	19.97%	David RisingerLeerink Partners 78%	309 342	Previous Outperform Current Outperform	Get Alert
Nov 2, 2026	BTSGBrightSpring Health	$69.74	31.92%	Whit MayoLeerink Partners 65%	72 92	Previous Outperform Current Outperform	Get Alert
Nov 2, 2026	REGNRegeneron Pharmaceuticals	$966.41	3.17%	David RisingerLeerink Partners 78%	835 997	Previous Market Perform Current Market Perform	Get Alert
Nov 2, 2026	THCTenet Healthcare	$267.00	28.09%	Whit MayoLeerink Partners 65%	309 342	Previous Outperform Current Outperform	Get Alert
Nov 2, 2026	NETCloudflare	$271.91	17.69%	Joseph GalloJefferies 78%	320 350	Previous Hold Current Hold	Get Alert
Nov 2, 2026	SFMSprouts Farmers Market	$52.20	20.7%	Christopher MandevilleJefferies 42%	63 95	Previous Buy Current Buy	Get Alert

Recent Analyst Stock Rating News

PRO

Freedom Capital Markets Maintains Buy on Hinge Health, Raises Price Target to $135

Freedom Capital Markets analyst Gene Mannheimer maintains Hinge Health (NYSE:HNGE) with a Buy and raises the price target from $103 to $135.

PRO

Jones Trading Maintains Buy on Angel Oak Mortgage REIT, Lowers Price Target to $9.5

Jones Trading analyst Matthew Erdner maintains Angel Oak Mortgage REIT (NYSE:AOMR) with a Buy and lowers the price target from $10.5 to $9.5.

PRO

TD Securities Maintains Sell on Imperial Oil, Raises Price Target to C$164

TD Securities analyst Menno Hulshof maintains Imperial Oil (TSX:IMO) with a Sell and raises the price target from C$158 to C$164.

PRO

Ladenburg Thalmann Maintains Neutral on Public Service Enterprise, Lowers Price Target to $75.5

Ladenburg Thalmann analyst Paul Fremont maintains Public Service Enterprise (NYSE:PEG) with a Neutral and lowers the price target from $80.5 to $75.5.

PRO

Lake Street Maintains Buy on Aehr Test System, Lowers Price Target to $90

Lake Street analyst Max Michaelis maintains Aehr Test System (NASDAQ:AEHR) with a Buy and lowers the price target from $110 to $90.

PRO

Lake Street Maintains Buy on NAPCO Security Techs, Lowers Price Target to $46

Lake Street analyst Jaeson Schmidt maintains NAPCO Security Techs (NASDAQ:NSSC) with a Buy and lowers the price target from $50 to $46.

PRO

Jefferies Maintains Buy on Aehr Test System, Lowers Price Target to $140

Jefferies analyst Kevin Garrigan maintains Aehr Test System (NASDAQ:AEHR) with a Buy and lowers the price target from $175 to $140.

PRO

Jefferies Upgrades Tempus AI to Hold, Raises Price Target to $70

Jefferies analyst Tycho Peterson upgrades Tempus AI (NASDAQ:TEM) from Underperform to Hold and raises the price target from $35 to $70.

PRO

Jefferies Maintains Buy on Check Point Software Tech, Lowers Price Target to $175

Jefferies analyst Joseph Gallo maintains Check Point Software Tech (NASDAQ:CHKP) with a Buy and lowers the price target from $185 to $175.

PRO

Needham Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $114

Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $130 to $114.

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

What Are Analyst Stock Ratings?

Analyst ratings measure the expected performance of a stock during a given time period. Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders.

Analysts arrive at stock ratings after they research companies’ public financial statements, communicate with executives and customers and interact with companies in other ways.

Most analysts issue ratings 4 times a year, usually at 3-month intervals.

How to Use Analyst Ratings

As an investor or trader, you want to be able to use analyst ratings effectively. Here are steps you can take to understand how to synthesize all the information analysts report about a particular company and how to apply it to your own trades.

Step 1: Check Ratings History

In the short term, look to see whether analysts suggest an initiation, upgrade or downgrade for a particular stock. Understand how the rating changed compared to the previous rating and whether a price target gets announced or changed.

Sometimes the rating stays the same and only the price target changes, which could cause the stock to move in either direction, depending on the significance of the change between the 2 price targets.

Step 2: Check for Other News

In the short term, check to see how the stock reacts to positive or negative news. This will be an indication of the company’s outlook because analyst ratings usually come out after the company announces news (it’ll typically be earnings news).

Step 3: Look at the Sector for News

Check to see if other stocks in the sector also received similar ratings. This could indicate micro news, which refers to when the whole sector or specific company trades in a specific way due to news outside of one company.

Step 4: Look at the Note

If available, look over the analyst note itself. The beginning of the note has the main information of the rating and price target. Investors should also take a look at the summary of the note, which you can find in the first couple pages and give you a concrete overview of the company. This can help you get an understanding of how analysts arrived at their thesis on the stock.

An example of an analyst note. Source: Needham

Step 5: Make a Decision

After reviewing the analyst ratings (and whether the analyst proposes a change or initiation) and find the reason for that note. Make a decision based on the analyst thesis on the company. This should give you guidance on how to make your thesis. Analyst ratings are a good indication of what professionals believe the company or sector will do, helping you get a better understanding of the companies you’re interested in.

Analyst Rating Accuracy

Analyst ratings are not set in stone and nobody knows indefinitely what a stock will do. Therefore, analyst ratings should be taken as an educated guess made by professionals who carefully study the specific company and sector in question. It's not a surprise that the accuracy of each rating can vary by each individual analyst and specific ratings on companies.

In other words, there’s no hard number or percentage on how accurate analyst ratings are because they are like educated guesses on what they think the stock will do based on their research, within that particular sector. In addition, each firm has so many analysts and so many different companies to review that you can compare ratings to glean what you believe is the truth.

Where Analyst Ratings Come From

Analyst ratings come from stock analysts. Analysts “go deep” on companies within a particular industry or sector. Some analysts employ a top-down approach (they start with an industry or sector and look for excellent companies within that industry or sector) and other stock analysts choose a bottom-up approach, which means they start with the company first and connect the dots within that company’s sector or industry. Analysts evaluate:

Financial statements
Economic fundamentals
Suppliers, customers and competitors
Management quality
Business model
Revenue
Expenses
Assets
Liabilities

While these evaluations are done using facts and figures that any investor can access, they come down to a conclusion the analyst must draw. While this isn’t an unqualified opinion, analysts will disagree because their interpretations of the data could vary.

Types of Stock Ratings

Stock ratings can range from simple “buy” and “sell” ratings to “equal weight” and “outperform” ratings. Here’s a quick overview of how analysts rate stocks.

Buy Rating

A “buy” rating indicates that an analyst is optimistic about a stock’s short-term or mid-term growth and recommends that traders purchase the stock. An analyst may even go so far as to indicate that a stock is a “strong buy.” At the same time, you may choose to swing trade the asset for a profit and come back later to start the process all over again.

Sell Rating

A “sell” rating means that an analyst believes the stock will trend downward in a particular time frame. Analysts might even refer to a security as a “strong sell.” Remember, though, you may want to swing trade and come back to this asset in the future even though you just chose to sell, just as you would under a “buy” rating.

Hold

A “hold” rating suggests that investors should not buy more of or sell the specified stock because they believe the stock should perform in a way that’s consistent with the market or will perform similarly to comparable companies within that particular sector. This is akin to the value investing approach that Warren Buffett uses, looking to gain long-term value from a single stock rather than flipping it because of a bad week. As many have said, it’s not a loss until you sell.

Underperform

An “underperform” rating means an analyst indicates that a stock is expected to perform below the market or sector average. And yes, while the underperform rating may not bode well for an asset in the next few weeks, it may not stay that way. Continue to carefully monitor your portfolio to ensure that an underperforming asset hasn’t turned itself around. As companies are faced with the Herculean task of pleasing shareholders, they will push to fix their underperforming stocks, meaning that a stock you wrote off could rise again.

Outperform

An “outperform” rating means that an analyst expects a stock to outperform the market or sector average. While the stock may look to outperform the market or a sector’s average, that doesn’t mean it will continue to soar forever. You must look at an outperform rating as what that asset will do in recent times, but it may not maintain that trajectory.

Equal-Weight

An equal weight rating means that an analyst believes that an individual stock's performance will tie to the average of all the stocks that an analyst covers in that particular sector. This type of rating helps investors get a true comparison of stocks to each other within a particular sector or industry. At the same time, equal-weight ratings could change at any time.

Price Target

A price target is an analyst’s projection of a stock’s future price. A price target is generally set up in a general trade or area where the asset might land. This means that the analyst could get close without hitting the figure on the head. Even so, the analyst wants to get close and better predict the movement of the marketplace and the asset.

Understanding Stock Ratings

Stock ratings are assessments of the investment potential of a particular stock. They are typically created by financial analysts who evaluate a company's financial performance, competitive positioning, and market outlook to provide guidance on the stock's expected future performance.

Ratings typically range from "buy" to "sell," with variations in between, such as "hold," "accumulate," or "neutral." A "buy" rating suggests that the stock is likely to perform well in the future, and investors should consider purchasing it. Conversely, a "sell" rating indicates that the stock is expected to underperform, and investors should consider selling it.

It's important to note that ratings are not guarantees of performance and should not be relied upon solely when making investment decisions. Ratings are just one factor to consider when evaluating a stock's potential, and investors should also conduct their own research and analysis to make informed decisions.

Another thing to keep in mind is that different analysts may have different opinions on a stock, so it's a good idea to consider multiple ratings before making an investment decision.

In addition to analyst ratings, investors can also consider other factors when evaluating a stock, such as its financial statements, management team, industry trends, and overall market conditions. By combining all of these factors, investors can make informed decisions about which stocks to buy or sell.

In summary, stock ratings are an important tool for investors to consider when evaluating a stock's potential, but they should not be the only factor used in investment decision-making. It's important to conduct your own research, consider multiple ratings, and take into account other factors before making an investment decision.

Should You Use Analyst Ratings to Inform Your Own Trades?

You can definitely use analyst ratings to inform your own trades and inform your own thesis but it’s a good idea to do your own research. However, analyst ratings are just one step in what should be a much larger investment strategy. Don’t fall in love with just one analyst. Compare notes. Look into how these ratings match with activity on the market and current events. Plus, remember that an analyst rating could easily be incorrect. No one is perfect, but these ratings are a good place to start.

Visit Benzinga News for more guidance on how to research companies and make decisions about research, trading and investing.

Compare Online Stock Brokers

Claim Exclusive Offers

Interactive Brokers Review
Good Fit For:
Active and Global Traders
VIEW PROS & CONS:
Securely through Interactive Brokers’ website
Plus500 Review
Good Fit For:
Leveraged Trading
VIEW PROS & CONS:
securely through Plus500 Yield's website
public.com Review
Good Fit For:
Trading Ideas
VIEW PROS & CONS:
securely through public.com's website
Robinhood Review
Good Fit For:
Commission-Free Mobile Trading
VIEW PROS & CONS:
securely through Robinhood's website
TradeZero Review
Good Fit For:
Active Short Sellers
VIEW PROS & CONS:
securely through TradeZero [SPONSORED]'s website